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Keywords Abstract 
Anaphylaxis In vitro experiments have related anaphylactoid reactions in patients treated 
Angiotensin-Converting enzyme with angiotensin-converting enzyme (ACE) inhibitors during dialysis with 
inhibitors AN69 membranes to excessive bradykinin generation using this negatively 
Bradykinin charged dialysis membrane. In the present clinical trial plasma bradykinin 
Dialysis, AN69 dialyzers levels were followed during the early phase of dialysis in 10 patients, not being 
treated with ACE inhibitors, using AN69, cuprophane, and polysulfone mem-
branes. Bradykinin was measured after extraction by radioimmunoassay. 
During this study one episode of anaphylaxis occurred during dialysis with the 
AN69 membrane. Blood samples were collected during the first 5 min of the 
adverse reaction and showed a more than 100-fold increase in the venous 
effluent of the AN69 dialyzer (baseline 40 ± 3 vs. 4,900 ± 130 fmol/ml after 
5 min). Even though none of the patients received ACE inhibitors, there were 
4 more asymptomatic individuals who displayed a more than two-fold 
increase in their plasma bradykinin concentrations in the venous effluent of 
the AN69 dialyzer. When these patients were treated either with cuprophane 
or with polysulfone dialyzers, no significant bradykinin formation was de-
tected, nor were there any adverse events. Taken together, these findings show 
that anaphylactoid reactions with the AN69 membrane are due to excessive 
bradykinin generation which even may occur in the absence of ACE inhibi-
tors. 
Introduction 
In 1990 two studies from Belgium appeared in the lit-
erature which reported on anaphylactoid reactions during 
dialysis with AN69 membranes in patients being treated 
with angiotensin-converting enzyme (ACE) inhibitors [1, 
2]. These observations triggered a host of other publica-
tions, reporting similar events during dialysis with AN69 
membranes [3-6]. Reports from the early 1980s had pri-
marily addressed hypersensitivity reactions associated 
with cuprophane [7, 8] or ethylene oxide membranes [9], 
while the more recent reactions occurred exclusively with 
AN69 dialyzers with and without the simultaneous use of 
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patients in Europe, Verresen et al. [10] demonstrated that 
out of 72 patients treated with AN69 membranes and 
ACE inhibitors 42 suffered from hypersensitivity reac-
tions, while 71 individuals treated with ACE inhibitors 
but dialyzed with other membranes were free of these side 
effects. Only 2 out of these 519 patients who were dia-
lyzed with AN69 membranes but did not receive ACE 
inhibitors developed anaphylactoid reactions. 
These observations provided strong empirical evi-
dence that the combination of dialysis with AN69 mem-
branes and ACE inhibition was involved in the evolution 
of these reactions. In terms of the underlying mechanism, 
it was hypothesized that the negatively charged AN69 
membrane could activate Hageman factor (factor XII) 
which at least has been shown in vitro [11]. Active Hage-
man factor in turn would convert prekallikrein into kalli-
krein. This proteinase could then cleave bradykinin from 
high-molecular-weight kininogen [12]. 
As ACE inhibitors also block the degradation of kinins 
[13] by inhibition of kininase II (= ACE), bradykinin 
could readily accumulate during the first few minutes of 
dialysis, until the membrane is covered by plasma pro-
teins. 
Up to now, this hypothesis has only been tested in 
vitro. Lemke and Fink [14] compared cuprophane and 
AN69 membranes in terms of bradykinin generation in 
vitro. In the absence of ACE inhibitors there was little 
bradykinin formation, while in the presence of ACE 
inhibitors seven-fold higher plasma levels of bradykinin 
were found during incubation with AN69 as compared 
with cuprophane membranes. Comparable in vitro results 
were obtained by Schulman et al. [15] who observed, in 
comparison with cuprophane, 6- to 15-fold higher plasma 
levels of bradykinin during incubation with AN69 mem-
branes. In terms of kallikrein formation, plasma levels of 
kallikrein-Cl inactivator complexes were 10- to 20-fold 
higher with the AN69 membrane. 
In the present study, bradykinin generation was fol-
lowed in vivo under standard hemodialysis conditions 
with AN69, cuprophane, and polysulfone membranes. 
For obvious ethical reasons, patients with concomitant 




Ten long-term hemodialysis patients (3 females, 7 males) gave 
their informed consent to participate in this investigation. Their 
mean age was 57 years (range 21-68 years), and on average they were 
dialyzed for 36 months (range 3-112 months). Patients who were 
treated with ACE inhibitors or those who had a history of hypersensi-
tivity reactions were excluded from the trial. The patients were nor-
mally treated either with cuprophane or polysulfone dialyzers. Since 
1990 AN69 membranes were no longer routinely used in our dialysis 
center. 
Dialyzers 
Three different dialyzers were evaluated in this study: ( 1 ) cupro-
phane (GFE 12, Gambro, 1.3 m2, ETO sterilized); (2) AN69 (Filtrai 
12, Hospal, 1.3 m2 , ETO sterilized), and (3) polysulfone (F60, Frese-
nius, 1.2 m2, ETO sterilized). 
The order of membranes was randomized for each patient. Prior 
to dialysis, the dialyzers were rinsed with 2 liters of heparinized 
(2,000 U/l) isotonic (0.9%) saline with an ultrafiltration rate of 
500 ml/h for the cuprophane and of 1,000 ml/h for the high-flux 
membranes. Patient connection was performed with a blood flow 
rate of 200 ml/min. 
Blood Sampling 
Timed blood samples (2 ml) were drawn prior to and during the 
first 20 min of dialysis into chilled polypropylene syringes which con-
tained 0.2 ml of a specific cocktail of proteinase inhibitors in order 
toblock kallikrein (kinin production) as well as the kininases I 
and II (kinin degradation). This mixture consisted of aprotinin 
(10,000 KJU/ml), soybean trypsin inhibitor (0.8 mg/ml), Polybrene 
(4.0 mg/ml), 1,10-phenanthrolene (10.0 mg/ml), and EDTA 
(20.0 mg/ml). Samples were collected both before and after dialysis. 
Bradykinin Assay 
Plasma kinin levels were analyzed according to the method of 
Shimamoto et al. [16, 17]. Before the kinin measurement, a repeated 
extraction procedure had to be performed. Briefly, 0.8 ml of plasma 
was incubated with 1.6 ml of cold ethanol. After 15 min, the sample 
was centrifuged at 4°C for 10 min. The supernatant was then evapo-
rated overnight at 40 °C and redissolved in 0.6 ml of 66% acetone. 
Thereafter, the sample was washed with 1.4 ml of petroleum ether 
and centrifuged for phase separation at room temperature. The 
upper layer was aspirated and discarded, while the lower layer was 
again evaporated overnight. 
Phosphate-buffered saline containing kininase inhibitors (30 mM 
EDTA and 30 m M 1,10-phenantroline) and 1% egg albumin was 
used as assay buffer. The antisynthetic bradykinin antibody (rabbit) 
was kindly provided by Dr. Shimamoto (Sapporo, Japan). Radioiodi-
nated synthetic tyrosyl bradykinin (400 uCi/ug) was prepared by the 
chloramine-T method (3,000 cpm/tube). The second antibody was a 
donkey antirabbit IgG. The radioactivity of the precipitate was mea-
sured by gamma counting. The assays were evaluated by the spline 
approximation method using a commercially available computer 
program (RIALOG II; Zinser Analytic, Frankfurt, FRG). All samples 
were measured in triplicate. The reproducibility of the assay was 
determined routinely at concentrations of 15, 180, and 750 fmol/ml. 
The coefficients of variation at these levels were 19, 14, and 17, 
respectively. 
Statistics 
All results are expressed as mean values ± SEM. The significance 
was tested using the Student t test. Differences were considered sig-
nificant when p < 0.05. 
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Fig. 1. Individual plasma bradykinin 
concentrations in the venous effluent during 
the early phase of AN69 dialysis. In the 
symptomatic patient data are only available 
for the first 5 min because the dialysis ses-
sion had to be interrupted thereafter. 
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Results 
Clinically, dialysis treatment with cuprophane and po-
lysulfone membranes was tolerated well, and there were 
no adverse events in all patients studied. By contrast, one 
severe anaphylactoid reaction occurred in a patient who 
was treated with an AN69 dialyzer. The symptoms only 
abated when dialysis with the AN69 membrane was 
stopped and the patient switched to polysulfone. 
As a measure of bradykinin generation, the plasma 
bradykinin concentrations in the venous effluent from 
AN69 dialyzers are shown in figure 1. As can be seen, 
there was 1 patient who displayed extremely high brady-
kinin levels in the venous effluent 3 and 5 min after the 
onset of treatment (5 min: 4,900 ± 130 fmol/ml). This 
excessive bradykinin generation was clinically associated 
with a severe anaphylactoid reaction which only abated 
when dialysis was stopped after 5 min. There were 4 more 
patients with bradykinin levels in excess of 100 fmol/ml 
in the venous effluents during the first minutes of dialysis 
who were clinically asymptomatic (fig. 1). Arterial plasma 
bradykinin levels (samples drawn before the dialyzer) 
remained below 100 fmol/ml in all patients (data not 
shown) which held also true for the individual who suf-
fered from the anaphylactoid reaction and displayed these 
excessive bradykinin levels in the venous effluent of the 
dialyzer. 
That bradykinin generation during hemodialysis is a 
membrane-specific event is depicted in figure 2. The 
same cohort of patients was dialyzed also with cupro-
phane and polysulfone membranes. The mean plasma 
bradykinin concentrations in the venous effluent re-
mained unchanged from baseline with both cuprophane 
and polysulfone membranes, but increased significantly 
when AN69 was used for dialysis. This difference was sig-
nificant, even though the data from the symptomatic 
patient were not included, when mean values were calcu-
lated for the AN69 membrane. 
Discussion 
To our knowledge, the present report is the first to pro-
vide evidence in humans that AN69-related anaphylac-
toid reactions are in all likelihood based on excessive bra-
dykinin generation within the dialyzer. By comparing 
arterial and venous plasma bradykinin concentrations 
(< 100 vs. 4,900 fmol/ml), it was clearly shown that brady-
kinin was generated within the AN69 dialyzer. This find-
ing also reveals how effectively bradykinin is degraded 
within the circulation, as long as kininases are not blocked 
by ACE inhibitors. 
As this observation is merely based only on a single 
case, it might seem somewhat farfetched to postulate a 
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Fig. 2 . Plasma bradykinin concentrations 
in the venous effluent of various dialyzers 
during the first 20 min of treatment. The 
AN69 curve does not include data from the 
symptomatic patient. Results are given as 
mean values ± SEM. p < 0.05 for AN69 ver-
sus other membranes. 
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general pathomechanism. However, besides the in vitro 
data reported by Schulman et al. [15] which fit well to our 
observations, there are preliminary data from experimen-
tal dialysis procedures with AN69 dialyzers in sheep that 
further strengthen the bradykinin hypothesis [18]. Both 
animals with (n = 8) and without (n = 8) Captopril dis-
played significant bradykinin generation within the AN69 
dialyzer which was more pronounced in sheep receiving 
ACE inhibitors. Anaphylactoid reactions were only ob-
served in the group of captopril-treated animals dialyzed 
with AN69 membranes. 
In our clinical study, bradykinin generation was strict-
ly membrane specific, occurring only during dialysis with 
AN69, but not with cuprophane or polysulfone mem-
branes. This pattern also has been observed in vitro with 
normal and uremic blood where significant activation of 
factor XII and kallikrein and subsequent bradykinin gen-
eration occurred only in the presence of AN69 mem-
branes [ 15]. In addition, in experimental dialysis in sheep, 
significant bradykinin concentrations were only found in 
the venous effluent of AN69 dialyzers [18]. 
Finally, the present trial also demonstrates that brady-
kinin generation and anaphylactoid reactions do occur 
during AN69 dialysis even in the absence of ACE inhibi-
tors. As can be seen from figure 1, there was a number of 
patients who displayed moderate bradykinin generation 
during dialysis with AN69 membranes without suffering 
from anaphylaxis. It is well conceivable that these indi-
viduals would have become clinically symptomatic when 
their kininase II would have been blocked by ACE inhibi-
tors. This is in agreement with the clinical results reported 
by Parnes and Shapiro [6] who observed AN69-related 
adverse reactions without concomitant ACE inhibition. 
Taken together, this report, even though being based 
on a limited number of patients, provides good evidence 
for the notion that anaphylactoid reactions during dialysis 
with AN69 membranes are due to excessive bradykinin 
generation which even may occur in the absence of ACE 
inhibitors. 
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